0001213900-13-004565.txt : 20130816 0001213900-13-004565.hdr.sgml : 20130816 20130816171056 ACCESSION NUMBER: 0001213900-13-004565 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130816 DATE AS OF CHANGE: 20130816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medifirst Solutions, Inc. CENTRAL INDEX KEY: 0001522704 STANDARD INDUSTRIAL CLASSIFICATION: CIGARETTES [2111] IRS NUMBER: 273888260 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-178412 FILM NUMBER: 131046162 BUSINESS ADDRESS: STREET 1: 4400 NORTH FEDERAL HWY, SUITE 54, CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-558-6872 MAIL ADDRESS: STREET 1: 4400 NORTH FEDERAL HWY, SUITE 54, CITY: BOCA RATON STATE: FL ZIP: 33431 10-Q 1 f10q0613_medifirst.htm QUARTERLY REPORT f10q0613_medifirst.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: June 30, 2013

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to _________

Commission File Number:
333-178825

MEDIFIRST SOLUTIONS, INC.
 (Exact name of registrant as specified in its charter)

NEVADA
 
27-3888260
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification Number)
 
50 Oxford Road, Manalapan, NJ, 07726
 (Address of principal executive offices)

732-786-8044
 (Issuer’s telephone number)

(Former name, former address and former fiscal year, if changed since last report) N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes o  No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company.  See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

(check one)  Large accelerated filer o          Accelerated filer o          Non-accelerated filer o           Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o  No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.  As of May 17, 2013, there were 7,881,750 shares of Common Stock, $0.0001 par value, outstanding and 0 shares of Preferred Stock, .0001 par value, outstanding.

 
 

 
 
PART I. FINANCIAL INFORMATION
 
     
Item  1.
Financial Statements.
3
     
Item  2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
15
     
Item  3.
Quantitative and Qualitative Disclosures About Market Risk.
18
     
Item  4.
Controls and Procedures.
18
     
PART II.  OTHER INFORMATION
 
     
Item 1.
Legal Proceedings.
18
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
18
     
Item 3.
Defaults Upon Senior Securities.
19
     
Item 4.
Mine Safety Disclosures
19
     
Item 5.
Other Information.
19
     
Item 6.
Exhibits.
19
 
 
 

 
 
PART I. FINANCIAL INFORMATION
 
Item 1. Financial Statements.
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Condensed Balance Sheets
June 30, 2013 and December 31, 2012
 
   
June 30,
   
December 31,
 
   
2013
   
2012
 
ASSETS
 
(Unaudited)
       
             
Current Assets:
           
Cash
  $ 2,176     $ 474  
Inventory
    4,000       -  
Total current assets
    6,176       474  
                 
Property, Plant and Equipment, net
    5,314       5,429  
                 
Other Assets
               
Security deposit
    265       265  
                 
    $ 11,755     $ 6,168  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
                 
Liabilities
               
    Accounts payable and accrued expenses
  $ 167,834     $ 111,470  
    Loans payable - stockholders
    26,312       27,214  
    6% convertible notes
    24,720       25,650  
    Total current liabilities
    218,866       164,334  
                 
Stockholders' Equity:
               
    Preferred stock, $0.0001 par value; 1,000,000 shares authorized, no shares issued and outstanding
    -       -  
    Common stock, $0.0001 par value; 200,000,000 shares authorized, 8,231,750 and 6,671,750 shares issued and outstanding, respectively
    823       667  
    Additional paid in capital
    57,385       56,611  
    Deficit accumulated during development stage
    (265,319 )     (215,444 )
      (207,111 )     (158,166 )
                 
    $ 11,755     $ 6,168  
 
See accompanying notes to unaudited condensed  financial statements.

 
3

 
Medifirst Solutions, Inc.
(A Development Stage Company)
Condensed Statements of Operations
For the Six Months Ended June 30, 2013 and 2012 and for the Period
From November 8, 2010  (Inception) to June 30, 2013
 
   
From November 8,
   
For the Three Months
   
For the Six Months
 
   
2010 (Inception)
   
Ended June 30,
   
Ended June 30,
 
   
to June 30, 2013
   
2013
   
2012
   
2013
   
2012
 
                               
Consulting fee revenue
  $ 58,300     $ -     $ -     $ 25,000     $ -  
Product sales, net
    16,040       5,081       -       5,081       -  
      74,340       5,081       -       30,081       -  
Cost of goods sold
    6,669       4,776       -       4,776       -  
Gross profit
    67,671       305       -       25,305       -  
                                         
Expenses:
                                       
Officer's compensation
    157,500       25,000       -       50,000       -  
Advertising and promotion
    24,320       4,725       250       4,912       1,921  
Computer and internet
    10,264       436       1,187       852       2,329  
Professional fees
    36,003       3,003       7,974       3,762       15,093  
Rent
    5,900       -       892       -       1,475  
Repairs and maintenance
    6,827       -       124       -       187  
Trade shows
    4,347       447       -       4,347       -  
Travel
    27,378       5,158       2,906       5,511       5,167  
Other
    57,595       429       4,078       4,655       9,828  
      330,134       39,198       17,411       74,039       36,000  
                                         
       Net loss before other income and expenses
    (262,463 )     (38,893 )     (17,411 )     (48,734 )     (36,000 )
                                         
Other income and (expenses)
                                       
Interest expense
    (2,856 )     (591 )     (432 )     (1,141 )     (682 )
Provision for income taxes
    -       -       -       -       -  
      (2,856 )     (591 )     (432 )     (1,141 )     (682 )
                                         
Net loss
  $ (265,319 )   $ (39,484 )   $ (17,843 )   $ (49,875 )   $ (36,682 )
                                         
Basic and diluted loss per share
  $ (0.04 )   $ (0.00 )   $ (0.00 )   $ (0.01 )   $ 0.00  
                                         
Basic and diluted weighted average number  of shares outstanding
    5,963,348       5,038,526       6,237,536       4,542,647       4,084,592  
 
See accompanying notes to unaudited condensed  financial statements.

 
4

 

Medifirst Solutions, Inc.
(A Development Stage Company)
Statement of Stockholders' Equity
For the Period from November 8, 2010 (Inception) to June 30, 2013
                                 
Accumulated
       
                           
Additional
   
Deficit During
   
Total
 
   
Common Stock
   
Preferred Class A
   
Paid in
   
Development
   
Stockholders'
 
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Stage
   
Equity
 
Issuance of common shares for services $0.0001 per share
    752,000     $ 75       -     $ -     $ -     $ -     $ 75  
Issuance of common shares for cash at at $0.08 per share
    81,250       8       -       -       6,492       -       6,500  
Issuance of common shares for cash at at $0.08 per share
    37,500       4       -       -       2,996       -       3,000  
Issuance of common shares for cash at at $0.08 per share
    125,000       12       -       -       9,988       -       10,000  
Issuance of common shares for cash at $0.00133 per share
    187,500       19       -       -       231       -       250  
Issuance of common shares for cash at at $0.02 per share
    12,500       1       -       -       249       -       250  
Issuance of common shares for services at $0.08 per share
    125,000       12       -       -       9,988       -       10,000  
Issuance of common shares for cash at $0.01 per share
    25,000       3       -       -       247       -       250  
Issuance of common shares for cash at $0.002 per share
    315,000       32       -       -       598       -       630  
Net loss
    -       -                       -       (4,457 )     (4,457 )
Balance - December 31, 2010
    1,660,750       166       -       -       30,789       (4,457 )     26,498  
                                                         
Issuance of common shares for cash at $0.0034 per share
    250,000       25       -       -       825       -       850  
Issuance of common shares for cash at $0.01 per share
    25,000       2       -       -       248       -       250  
Issuance of common shares for cash at $0.016 per share
    12,500       1       -       -       199       -       200  
Issuance of common shares for cash at $0.0019 per share
    75,000       8       -       -       135       -       143  
Issuance of common shares for cash at $0.0014 per share
    250,000       25       -       -       325       -       350  
Issuance of common shares for services $0.002 per share
    3,750,000       375       -       -       7,125       -       7,500  
Issuance of common shares for cash at $0.0167 per share
    300,000       30       -       -       4,970       -       5,000  
Issuance of common shares for services $0.08 per share
    20,000       2       -       -       1,598       -       1,600  
Issuance of common shares for cash at $0.08 per share
    6,250       1       -       -       499       -       500  
Issuance of common shares for cash at $0.08 per share
    53,500       5       -       -       4,275       -       4,280  
Issuance of common shares for cash at $0.08 per share
    12,500       1       -       -       999       -       1,000  
Subtotals
    6,415,500       641       -       -       51,987       (4,457 )     48,171  
                                                         
Subtotals
    6,415,500     $ 641       -     $ -       51,987     $ (4,457 )   $ 48,171  
Issuance of common shares for cash at $0.04 per share
    100,000       10       -       -       3,990       -       4,000  
Issuance of common shares for cash at $0.08 per share
    6,250       1       -       -       499       -       500  
Net loss
    -       -       -       -       -       (36,788 )     (36,788 )
Balance - December 31, 2011
    6,521,750       652       -       -       56,476       (41,245 )     15,883  
                                                         
Issuance of common shares upon partial conversion of note at $0.001 per share
    150,000       15       -       -       135       -       150  
Net loss
    -       -       -       -       -       (174,199 )     (174,199 )
Balance - December 31, 2012
    6,671,750       667       -       -       56,611       (215,444 )     (158,166 )
                                                         
Issuance of common shares upon partial conversion of note at $0.001 per share
    660,000       66       -       -       594       -       660  
Issuance of common shares upon partial conversion of note at $0.001 per share
    200,000       20       -       -       180       -       200  
Issuance of common shares upon partial conversion of note at $0.0001 per share
    700,000       70       -       -       70       -       70  
Net loss
    -       -       -       -       -       (49,875 )     (49,875 )
Balance - June 30, 2013
    8,231,750     $ 823       -     $ -     $ 57,385     $ (265,319 )   $ (207,111 )
 
See accompanying notes to unaudited condensed  financial statements.

 
5

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Condensed Statements of Cash Flows
For the Six Months Ended June 30, 2013 and 2012 and for the Period
From November 8, 2010  (Inception) to June 30, 2013
 
   
From
             
   
November 8,
             
   
2010
(Inception) to
   
For the Six Months Ended
June 30,
 
   
June 30, 2013
   
2013
   
2012
 
                   
Cash flows from operating activities:
                 
    Net loss
  $ (265,319 )   $ (49,875 )   $ (36,682 )
    Adjustments to reconcile net loss to net cash used by operating activities:
                       
       Common stock issued for services
    9,175       -       -  
       Depreciation expense
    444       115       78  
       Inventory
    (4,000 )     (4,000 )     -  
       Security deposit
    (265 )     -       -  
       Accounts payable and accrued expenses
    167,834       56,364       (2,612 )
Net cash used by operating activities
    (92,131 )     2,604       (39,216 )
                         
Cash flows from investing activities:
                       
    Purchase of equipment
    (5,758 )     -       -  
Net cash used by investing activities
    (5,758 )     -       -  
                         
Cash flows from financing activities:
                       
    Proceeds from issuance of common stock
    49,033       930       -  
    Stockholder's loan
    26,312       (902 )     7,627  
    6% convertible notes
    24,720       (930 )     25,000  
Net cash provided by financing activities
    100,065       (902 )     32,627  
                         
Net increase in cash
    2,176       1,702       (6,589 )
Cash at beginning of period
    -       474       33,409  
Cash at end of period
  $ 2,176     $ 2,176     $ 26,820  
                         
Supplemental cash flow information:
                       
    Cash paid during the period for:
                       
       Interest
  $ 2,274     $ 205     $ 432  
       Income taxes
  $ -     $ -     $ -  
 
See accompanying notes to unaudited condensed  financial statements.

 
6

 

Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization

Medifirst Solutions, Inc. ("MSI" or the "Company") was incorporated in Nevada in November 2010.  The Company is in the development stage and has a diverse product line including both consumer products and digital media.  The Company has a Health & Wellness division with an LED Light Therapy System that it distributes.  The Company plans to launch "Florida Health Community" as an on-line healthcare directory and social media site geared towards both professionals and consumers.  MSI also intends to produce a tabloid size newsletter with healthcare industry related news and events.  MSI holds the trademark to, and will sell on-line, the Miracle-cigTM, an electronic cigarette that is tobacco free and that emits a fine water mist in place of smoke.  Additionally, MSI will offer print and digital marketing and advertising services to its client base of medical professionals as well as solicit new business in other business sectors.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information.  Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such principles and regulations of the Securities and Exchange Commission for Form 10-Q.  All adjustments, consisting of normal recurring adjustments, have been made which, in the opinion of management, are necessary for a fair presentation of the results of interim periods.  The results of operations for such interim periods are not necessarily indicative of the results that may be expected for a full year because of, among other things, seasonality factors in the retail business.  The unaudited financial statements contained herein should be read in conjunction with the audited financial statements and notes thereto  for the fiscal year ended December 31, 2012.

Revenue Recognition

In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. The following policies reflect specific criteria for the various revenues streams of the Company:

Revenue will be recognized at the time the product is delivered or services are performed.  Provision for sales returns will be estimated based on the Company's historical return experience.  Revenue will be presented net of returns.

 
7

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Segment Information

The Company follows Accounting Standards Codification ("ASC") 280, "Segment Reporting".  The Company currently operates in a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

Net Loss Per Common Share

Basic net (loss) income per common share is calculated using the weighted average common shares outstanding during each reporting period.  Diluted net (loss) income per common share adjusts the weighted average common shares for the potential dilution that could occur if common stock equivalents (convertible debt and preferred stock, warrants, stock options and restricted stock shares and units) were exercised or converted into common stock.

Income Taxes

Deferred income taxes are recognized for the tax consequences related to temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for tax purposes at each year end, based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.  A valuation allowance is recognized when, based on the weight of all available evidence, it is considered more likely than not that all, or some portion, of the deferred tax assets will not be realized.  Income tax expense is the sum of current income tax plus the change in deferred tax assets and liabilities.

ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information.  A tax position that meets this more likely than not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority.

 
8

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Stock-Based Compensation

The Company accounts for equity instruments issued to employees in accordance with ASC 718, Compensation - Stock Compensation.  ASC 718 requires all share-based compensation payments to be recognized in the financial statements based on the fair value using an option pricing model.  ASC 718 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates.

Equity instruments granted to non-employees are accounted for in accordance with ASC 505, Equity.  The final measurement date for the fair value of equity instruments with performance criteria is the date that each performance commitment for such equity instrument is satisfied or there is a significant disincentive for non-performance.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Inventory

Inventory consists of finished goods and is stated at the lower of cost (first-in, first-out) or market value.

Equipment

Equipment, consisting of computer equipment, is stated at cost less accumulated depreciation.  Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, of five years.

The Company reviews long-lived assets, such as equipment, for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.  If the carrying amount of an asset exceeds the estimated future cash flows, an impairment loss will be recorded by the amount the carrying value exceeds the fair value of the asset.

Recent Pronouncements

There are no recent accounting pronouncements that apply to the Company.

 
9

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 2.  EQUIPMENT (NET)

Equipment is recorded at cost and consisted of the following at June 30, 2013 and 2012:

   
2013
   
2012
 
Computer equipment
  $ 5,758     $ 5,758  
                 
Less: accumulated depreciation
    (444 )     (230 )
                 
    $ 5,314     $ 5,528  
 
Depreciation for the three months ended June 30, 2013 and 2012 was $115 and $78, respectively.
 
Note 3.  LOANS PAYABLE - STOCKHOLDERS

During the period ended June 30, 2013 a stockholder of the Company advanced the Company $9,757 to pay for certain expenses.  The loan has a balance of $16,312 at June 30, 2013, bears no interest and is payable on demand.

At June 30, 2013 the Company was indebted to a stockholder in the amount of $5,000.  The loan has an interest of 20%.  Principal and accrued interest were due and payable on July 2, 2012.

At June 30, 2013 the Company was indebted to a stockholder in the amount of  $5,000.  The loan has an interest of 10%.  Principal and accrued interest were due and payable on June 2, 2013.

Note 4.  6% CONVERTIBLE NOTES

In March 2011, the Company issued $800 aggregate principal amount of 6% convertible notes due in January 2012.  Interest on the notes accrued at the rate of 6% per annum for the term of the notes and was payable upon maturity.

In June 2013, two of the note holders converted $70 of note principal into 700,000 shares of the Company's common stock.

 
10

 

Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013
 
Note 4.  6% CONVERTIBLE NOTES (continued)

At any time on or after the maturity date, the holders of the notes, have the option of converting any of the unpaid principal and interest into the Company's common stock.  The notes plus any accrued but unpaid interest are convertible at the rate of $0.0001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013.

In May 2012, the Company issued a $25,000 6% per annum note that matured in November 2012.  In December 2012 the note was amended to be a convertible note.  Interest on the note accrues interest at 6% per annum and is payable when the note matures.

The holder of the $25,000 note has the option of converting it at any time with the approval of the Board of Directors.  The note plus any accrued but unpaid interest are convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013.

The holder of the note converted $1,010 of note principal into 1,010,000 shares of common stock as follows:

Date of Conversion
 
Principal
Amount
Converted
   
Conversion
Rate
 
Shares
Received
 
December 2012
  $ 150     $ 0.001     $ 150,000  
January 2013
  $ 660     $ 0.001     $ 660,000  
March  2013
  $ 200     $ 0.001     $ 200,000  

Note 5.  STOCKHOLDERS' EQUITY

In November 2010, the Company issued 752,000 shares of common stock at par value for services provided to the Company.

In November 2010, the Company issued 81,250 shares of common stock at $0.08 per share.

In November 2010, the Company issued 37,500 shares of common stock at $0.08 per share.

In December 2010, the Company issued 125,000 shares of common stock at $0.08 per share.

 
11

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 5.  STOCKHOLDERS' EQUITY (continued)

In December 2010, the Company issued 187,500 shares of common stock at $0.00133 per share.

In December 2010, the Company issued 12,500 shares of common stock at $0.02 per share.

In December 2010, the Company issued 125,000 shares of common stock at $.08 per share for services provided to the Company.

In December 2010, the Company issued 25,000 shares of common stock at $0.01 per share.

In December 2010, the Company issued 315,000 shares of common stock at $0.002 per share.

In January 2011, the Company issued 250,000 shares of common shares at $0.0034 per share.

In January 2011, the Company issued 25,000 shares of common shares at $0.01 per share.

In January 2011, the Company issued 12,500 shares of common shares at $0.016 per share.

In March 2011 the Company issued 75,000 shares of common stock at $0.0019 per share.

In March 2011 the Company issued 250,000 shares of common stock at $0.0014 per share.

In March 2011, the Company issued 3,750,000 shares of common stock to an officer of the Company for services provided to the Company at $0.002 per share.
 
In April 2011, the Company issued 300,000 shares of common stock at $0.0167 per share.

In October 2011, the Company issued 20,000 shares of common stock at $0.08 per share for services provided to the company.

 
12

 

Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 5.  STOCKHOLDERS' EQUITY (continued)

In October 2011, the Company issued 6,250 shares of common stock at $0.08 per share.

In November 2011, the Company issued 53,500 shares of common stock at $0.08 per share.

In November 2011, the Company issued 12,500 shares of common stock at $0.08 per share.

In December 2011, the Company issued 100,000 shares of common stock at $0.04 per share.

In December 2011, the Company issued 6,250 shares of common stock at $0.08 per share.

In December 2012, the Company issued 150,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).

In January 2013, the Company issued 660,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).

In March 2013, the Company issued 200,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).

In June 2013, the Company issued 700,000 shares of common stock at $0.0001 per share as partial conversion of a note (See note 4).

Note 6.  INCOME TAXES

The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.  The sources and tax effects of the differences are as follows:
 
Income tax provision at the federal statutory rate
   
               39
%
Effect of operating losses
   
             (39
)%
     
 0
%

 
13

 
 
Medifirst Solutions, Inc.
(A Development Stage Company)
Notes to Condensed Financial Statements
June 30, 2013

Note 6.  INCOME TAXES (continued)

As of June 30, 2013, the Company has a net operating loss carryforward of approximately $250,000.  This loss will be available to offset future taxable income.  If not used, this carryforward will begin to expire in 2030. The deferred tax asset relating to the operating loss carryforward has been fully reserved at June 30, 2013.  The principal difference between the operating loss for income tax purposes and reporting purposes results from the issuance of common shares for services.

Note 7.  BASIS OF REPORTING

The Company's financial statements are presented on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has experienced a loss from operations during its development stage as a result of its investment necessary to achieve its operating plan, which is long-range in nature.  For the period from inception to June 30, 2013, the Company incurred a net loss of approximately $265,000.  In addition, the Company has no significant assets or revenue generating operations.

The Company currently does not have sufficient cash to sustain itself for the next 12 months, and will require additional funding in order to execute its plan of operations and to continue as a going concern.  To meet its cash needs, management expects to raise capital through a private placement offering.  In the event that this funding does not materialize, certain stockholders have agreed, orally, to loan, on a non-interest bearing demand basis, sufficient funds to maintain the Company's operations for the next 12 months.

The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.
 
Note 8. SUBSEQUENT EVENTS
 
In July 2013, two notes were partially converted into 750,000 shares of the Company's common stock at the conversion rate of $0.001 per share.
 
In August 2013, one note was partially converted into 300,000 shares of the Company's common stock at the conversion rate of $0.001 per share.
 
 
14

 
 
MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This section must be read in conjunction with the Audited Financial Statements included in this Prospectus.
 
Plan of Operation
 
Medifirst Solutions, Inc. was incorporated in Nevada in November 2010.   We are in the development stage and have a diverse product line including both consumer products and digital media.  Since our inception, we have been engaged in business planning activities, including researching the industry, identifying target markets for our products, developing our models and financial forecasts, performing due diligence regarding potential geographic locations most suitable for establishing our offices and identifying future sources of capital.  At the present time, our initial products are Miracle-cigTM, an electronic cigarette that is tobacco free and that emits a fine water mist in place of smoke, and the Florida Health Community, an on-line healthcare directory and social media site geared towards both professionals and consumers.  Building off of the services we intend to offer through Florida Health Community, we also have began to offer print and digital marketing and consulting and advertising services to the member base of medical professionals from our Florida Health Community activities and those outside the membership community who wish to use our creative services. We have recently begun selling our product and services and generating revenue from our business operations. All of our operations are currently conducted through the Company and we do not have any subsidiaries.  See “Description of Business” contained herein.
 
Our auditors have issued a going concern opinion. This means that our auditors believe there is substantial doubt that we can continue as an on-going business for the next twelve (12) months. Our auditors’ opinion is based on the uncertainty of our ability to establish profitable operations. The opinion results from the fact that we have not generated significant revenues.  Accordingly, we must raise cash from operations or from investments by others in our Company to continue our operations.
 
Our sole officer and director is responsible for our managerial and organizational structure, which will include preparation of disclosure and accounting controls under the Sarbanes Oxley Act of 2002. When these controls are implemented, he will be responsible for the administration of the controls. Should he not have sufficient experience, he may be incapable of creating and implementing the controls which may cause us to be subject to sanctions and fines by the SEC which ultimately could cause you to lose your investment.
 
Our intended plan of operations is to generate revenue from our diverse divisions of operation. We believe that diversification of our interests will help generate revenues.
 
 
15

 
 
Health & Wellness Division
 
Medifirst Light Therapy Systems. Medifirst has launched a new Health and Wellness Division with a new and cutting-edge LED Botanical Light Therapy Systems.  Medifirst signed an agreement with Panacea Photonics whereas it is the exclusive distributor for New York and New Jersey for the LED Light Therapy Systems that incorporates rainforest botanicals in using the technology. The company plans on expanding and rolling out the systems to other parts of the country and will be attending a major tradeshows. Medifirst has attended trade shows in both New York and Orlando and will continue to introduce the LED systems to both the public and to healthcare professionals. The Botanical Light Therapy Systems will appeal to Doctors, Chiropractors, Acupuncturists,  Cosmetologists, Spa and Wellness Centers and most practitioners of Alternative Medicine. This sector represents thousands of healthcare professionals that fall within our exclusive territory and gives us a fantastic opportunity to greatly expand our client base and develop more products to add to our pipeline.” The patent-pending Light Therapy System, developed by Panacea Photonics, uses special botanical formulas to produce amazing results. The botanical solutions utilize highly researched and artfully blended South American Rain Forest botanicals and are rigorously tested to insure the highest levels of performance & safety. They are formulated with 100% all-natural, naturally harvested, hand-crafted, artfully blended & indigenous tribally sourced botanicals.
 
Miracle-cig
 
The Miracle-cig is a trademarked name for our brand of disposable electronic cigarette. It is sold online at www.miraclecig.com. We currently have a merchant account that accepts VISA and MASTERCARD for sales of the product through our website. The cost of the website and its development has already been paid for and the ongoing expenses for hosting the website are $50 per month. We purchase the Miracle-cig directly from the manufacturer in China. Orders are placed by purchase order and payment is made in advance. We place orders with our manufacturer only when we receive orders and payment from customers, thereby ensuring we have funds available for each order we place. We currently do not have any manufacturing or distribution agreement with our current manufacturer or with any other manufacturer. We fulfill orders within 24 hours and have small inventory. We are still seeking strategic partnerships and developing our SEO.
 
Our management planned on launching a new e-cig label and expanding into a new consumer market but has decided to wait until 2014. Additionally, we are still working our SEO and  seeking online affiliations.
 
Florida Health Community
 
Website and Newsletter. Medifirst has decided to expand its Health & Wellness division and related services in Florida and is currently reevaluating the The Florida Health Community website and Newsletter as to how it integrates into the newly formed wellness division. A decision is expected by the end of the year.
 
Advertising Agency. Medifirst Solutions will also expand to provide website, publishing, marketing, print and video production services for hire to the both healthcare and non healthcare professionals.  Many of the Medifirst clients are in need of a business website and other various promotional materials such as brochures, company logo, video promotions and editorial services. The company management anticipates that over the next twelve months we anticipate to continue to offer our and expand our creative services.
 
Results of Operations

Fiscal Year Ended December 31, 2013
 
 
16

 
 
Revenues
 
During the three months ended June 30, 2013 and 2012, we generated $ 5,081 and $-0- in revenues, respectively.
 
We expect revenues for the short term to remain minimal, however we believe revenues will increase after execution of our business plans.
 
Expenses
 
For the three months ended June 30, 2013 and 2012, expenses were $39,198 and $17,411, respectively.
 
We expect expenses for 2013 to trend upward as we continue to incur additional expenses necessary to grow our business.
 
Legal and Accounting
 
For the three months ended June 30, 2013 and 2012, professional fees were $3,003 and $7,974, respectively.
 
We expect professional fees for 2013 to trend marginally downward as we pursue operations in the ordinary course of business, though we will continue to incur additional expenses as a result of our being a publicly traded company.  This includes corporate legal, accounting, stockholder and SEC filing expenses.   
 
Other Income/(Expense)
 
For the three months ended June 30, 2013 and 2012, other expenses was  $591 and $432, respectively.
 
Expense for the three months ended June 30, 2013 consisted of interest expense.
 
Net Income/(Loss)
 
For the three months ended June 30, 2013 and 2012, the company had a net loss of $39,484 and $17,843.

Liquidity and Capital Resources

Since incorporation, we have financed our operations through the private placement of our common stock to selected investors and periodic borrowings from our stockholders.  At June 30, 2013 and 2012, our principal sources of liquidity included cash and cash equivalents of $2,176 and $26,820, respectively.
 
As of June 30, 2013, we did not have any significant commitments for capital expenditures.
 
If we do not generate sufficient cash flow to support our operations over the next twelve (12) months, in order to continue as a going concern we may need to raise additional capital by issuing capital stock in exchange for cash.  There are no formal or informal agreements to attain such financing.  The Company’s ability to obtain additional capital on acceptable terms is subject to a variety of uncertainties, including: investors’ perception of, and demand for, securities of companies in our industry; conditions of the U.S. and other capital markets in which we may seek to raise funds; future results of operations, financial condition and cash flow.  Therefore, the Company’s management cannot assure that financing will be available in amounts or on terms acceptable to the Company, or if at all.  Any failure by the Company’s management to raise additional funds on terms favorable to the Company could have a material adverse effect on the Company’s liquidity and financial condition.
 
 
17

 

Critical Accounting Policies
 
Our significant accounting policies are summarized in Note 1 of our consolidated financial statements.  While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical.  Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates.  Actual results may differ from those estimates.  Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause an effect on our consolidated results of operations, financial position or liquidity for the periods presented in this report.
 
Off Balance Sheet Arrangements
 
The Company has no off-balance sheet arrangements.

Recently Adopted Accounting Pronouncements

Please see Note 2 of our consolidated financial statements that describe the impact, if any, from the adoption of Recent Accounting Pronouncements.

Item 3. Quantitative and Qualitative Disclosures About  Market Risk.

The Company is a smaller reporting company, as defined by Rule 229.10(f)(1) and is not required to provide the information required by this Item.

Item 4. Controls and Procedures.
 
Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our principal executive and principal financial officers, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (the “Exchange Act”).  Based on that evaluation, our principal executive and financial officers concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
PART II.  OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Recent Sales of Unregistered Securities
On June 14, 2013, the Company issued 700,000 shares of common stock to two holders of convertible promissory notes upon the exercise of conversion rights by the holders.
 
 
18

 

Each of these transactions was exempt from the registrations requirements of the Securities Act of 1933, as amended, pursuant to Section 4 (2) thereof. In the alternative, the common stock  is an exempt security pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended.

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

None

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures


Item 5. Other Information.

There have been no material changes to the procedures by which security holders may recommend nominees to the Registrant’s board of directors.
 
Item 6. Exhibits.

31.1
Certification of the Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2
Certification of the Chief Executive Officer and Principal Executive Officer Pursuant to 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

32.1
Certification of the Chief Financial Officer and Principal Financial Officer Pursuant to 13a-14 and 15d-14 of the Securities Exchange Act of 1934.

 
19

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this quarterly report to be signed on its behalf by the undersigned hereunto duly authorized.
 
August 15, 2013
   
       
  By /s/ Bruce Schoengood  
   
Bruce Schoengood
Chief Executive Officer
(Principal Executive Officer)
 
       
  By  /s/ Bruce Schoengood  
   
Bruce Schoengood
Chief Financial Officer
(Principal Financial Officer)
 
 
 
20 

EX-31.1 2 f10q0613ex31i_medifirst.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. f10q0613ex31i_medifirst.htm
Exhibit 31.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULES 13A-14 AND 15D-14
OF THE SECURITIES EXCHANGE ACT OF 1934

I, Bruce Schoengood, certify that:

1)  
I have reviewed this quarterly report on Form 10-Q of  MEDIFIRST SOLUTIONS, INC;
   
2)  
Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3)  
Based on my knowledge, the financial statements and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
   
4)  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant , including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared.
     
 
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
     
 
d.  
Disclosed in this quarterly report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter  that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5)  
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
 
 
a.  
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
 
b.  
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date August 15, 201
  /s/ Bruce Schoengood  
   
Bruce Schoengood
 
   
Chief Executive Officer and President
(Principal Executive Officer)
 
EX-31.2 3 f10q0613ex31ii_medifirst.htm CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 13A-14 AND 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934. f10q0613ex31ii_medifirst.htm
Exhibit 31.2

CERTIFICATIONS OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULES 13A-14 AND 15D-14
OF THE SECURITIES EXCHANGE ACT OF 1934

I,  Bruce Schoengood, certify that:

1)  
I have reviewed this quarterly report on Form 10-Q of  MEDIFIRST SOLUTIONS, INC;
   
2)  
Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
   
3)  
Based on my knowledge, the financial statements and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
   
4)  
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a.  
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant , including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared.
     
 
b.  
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
c.  
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
     
 
d.  
Disclosed in this quarterly report any changes in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter  that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5)  
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):
 
  a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date August 15, 2013
 
/s/ Bruce Schoengood  
    Bruce Schoengood  
   
Chief Financial Officer
(Principal Financial Officer)
 
 
 
EX-32.1 4 f10q0613ex32i_medifirst.htm CERTIFICATION OF THE CHIEF FINANCIAL OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 13A-14 AND 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934. f10q0613ex32i_medifirst.htm
Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MEDIFIRST SOLUTIONS, INC. (“Company”) on Form 10-Q for the quarter ending May 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (“ Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1)  
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2)  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date August 15, 201
By /s/ Bruce Schoengood  
   
Bruce Schoengood
 
   
Chief Executive Officer
(Principal Executive Officer)
 
 
 
By
/s/ Bruce Schoengood  
    Bruce Schoengood  
   
Chief Financial Officer
(Principal Financial Officer)
 
EX-101.INS 5 medf-20130630.xml 0001522704 2010-11-09 2010-12-31 0001522704 us-gaap:CommonStockMember 2010-11-09 2010-12-31 0001522704 us-gaap:PreferredClassAMember 2010-11-09 2010-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2010-11-09 2010-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-11-09 2010-12-31 0001522704 2011-03-31 0001522704 2011-03-01 2011-03-31 0001522704 2011-01-01 2011-12-31 0001522704 us-gaap:CommonStockMember 2011-01-01 2011-12-31 0001522704 us-gaap:PreferredClassAMember 2011-01-01 2011-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-01-01 2011-12-31 0001522704 2012-05-31 0001522704 2012-05-01 2012-05-31 0001522704 2012-04-01 2012-06-30 0001522704 2012-01-01 2012-06-30 0001522704 2012-01-01 2012-12-31 0001522704 us-gaap:CommonStockMember 2012-01-01 2012-12-31 0001522704 us-gaap:PreferredClassAMember 2012-01-01 2012-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-01-01 2012-12-31 0001522704 2012-12-31 0001522704 us-gaap:ComputerEquipmentMember 2012-12-31 0001522704 2013-05-17 0001522704 2013-04-01 2013-06-30 0001522704 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityOneMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwoMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityFourMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityFiveMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivitySixMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivitySevenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityEightMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityNineMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityThreeMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityElevenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwelveMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityThirteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityFourteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityFifteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivitySixteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivitySeventeenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityEighteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityNineteenMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyOneMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyTwoMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyFourMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyFiveMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentySixMember 2013-01-01 2013-06-30 0001522704 us-gaap:CommonStockMember 2013-01-01 2013-06-30 0001522704 us-gaap:PreferredClassAMember 2013-01-01 2013-06-30 0001522704 us-gaap:AdditionalPaidInCapitalMember 2013-01-01 2013-06-30 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-01-01 2013-06-30 0001522704 medf:DateOfConversionOneMember 2013-01-01 2013-06-30 0001522704 medf:DateOfConversionTwoMember 2013-01-01 2013-06-30 0001522704 medf:DateOfConversionThreeMember 2013-01-01 2013-06-30 0001522704 medf:StockIssuanceActivityTwentySevenMember 2013-01-01 2013-06-30 0001522704 2013-06-30 0001522704 us-gaap:ComputerEquipmentMember 2013-06-30 0001522704 medf:LoanPayableDueOnJulyTwoTwoZeroOneTwoMember 2013-06-30 0001522704 medf:LoanPayableDueOnJuneSecondTwoZeroOneThreeMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwoMember 2013-06-30 0001522704 medf:StockIssuanceActivityFourMember 2013-06-30 0001522704 medf:StockIssuanceActivityFiveMember 2013-06-30 0001522704 medf:StockIssuanceActivitySixMember 2013-06-30 0001522704 medf:StockIssuanceActivitySevenMember 2013-06-30 0001522704 medf:StockIssuanceActivityEightMember 2013-06-30 0001522704 medf:StockIssuanceActivityNineMember 2013-06-30 0001522704 medf:StockIssuanceActivityThreeMember 2013-06-30 0001522704 medf:StockIssuanceActivityTenMember 2013-06-30 0001522704 medf:StockIssuanceActivityElevenMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwelveMember 2013-06-30 0001522704 medf:StockIssuanceActivityThirteenMember 2013-06-30 0001522704 medf:StockIssuanceActivityFourteenMember 2013-06-30 0001522704 medf:StockIssuanceActivityFifteenMember 2013-06-30 0001522704 medf:StockIssuanceActivitySixteenMember 2013-06-30 0001522704 medf:StockIssuanceActivitySeventeenMember 2013-06-30 0001522704 medf:StockIssuanceActivityEighteenMember 2013-06-30 0001522704 medf:StockIssuanceActivityNineteenMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyOneMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyTwoMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyFourMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentyFiveMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentySixMember 2013-06-30 0001522704 us-gaap:CommonStockMember 2013-06-30 0001522704 medf:DateOfConversionOneMember 2013-06-30 0001522704 medf:DateOfConversionTwoMember 2013-06-30 0001522704 medf:DateOfConversionThreeMember 2013-06-30 0001522704 medf:StockIssuanceActivityTwentySevenMember 2013-06-30 0001522704 2010-11-07 2013-06-30 0001522704 2013-06-01 2013-06-30 0001522704 us-gaap:SubsequentEventMember 2013-07-31 0001522704 us-gaap:SubsequentEventMember 2013-07-01 2013-07-31 0001522704 us-gaap:SubsequentEventMember 2013-08-31 0001522704 us-gaap:SubsequentEventMember 2013-08-01 2013-08-31 0001522704 2010-11-08 0001522704 2010-12-31 0001522704 us-gaap:CommonStockMember 2010-11-08 0001522704 us-gaap:CommonStockMember 2010-12-31 0001522704 us-gaap:PreferredClassAMember 2010-11-08 0001522704 us-gaap:PreferredClassAMember 2010-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2010-11-08 0001522704 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-11-08 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2010-12-31 0001522704 2011-12-31 0001522704 us-gaap:CommonStockMember 2011-12-31 0001522704 us-gaap:PreferredClassAMember 2011-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2011-12-31 0001522704 2012-06-30 0001522704 us-gaap:CommonStockMember 2012-12-31 0001522704 us-gaap:PreferredClassAMember 2012-12-31 0001522704 us-gaap:AdditionalPaidInCapitalMember 2012-12-31 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2012-12-31 0001522704 us-gaap:PreferredClassAMember 2013-06-30 0001522704 us-gaap:AdditionalPaidInCapitalMember 2013-06-30 0001522704 us-gaap:AccumulatedDeficitDuringDevelopmentStageMember 2013-06-30 0001522704 2010-11-06 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure medf:Segment Medifirst Solutions, Inc. 0001522704 10-Q 2013-06-30 false 2013 Q2 --12-31 Smaller Reporting Company 7881750 474 2176 33409 26820 474 6176 5429 5314 265 265 6168 11755 111470 167834 27214 26312 5000 5000 164334 218866 667 823 56611 57385 -215444 -265319 -158166 -207111 823 26498 166 30789 -4457 15883 652 56476 -41245 667 56611 -215444 57385 -265319 6168 11755 0.0001 0.0001 1000000 1000000 0.0001 0.0001 200000000 200000000 6671750 8231750 6671750 8231750 25000 58300 5081 5081 16040 5081 30081 74340 4776 4776 6669 305 25305 67671 25000 50000 157500 250 1921 4725 4912 24320 1187 2329 436 852 10264 7974 15093 3003 3762 36003 124 187 6827 2906 5167 5158 5511 27378 4078 9828 429 4655 57595 17411 36000 39198 74039 330134 -17411 -36000 -38893 -48734 -262463 432 682 591 1141 2856 -432 -682 -591 -1141 -2856 -4457 -4457 -36788 -36788 -17843 -36682 -174199 -174199 -39484 -49875 -49875 -265319 -0.00 0.00 -0.00 -0.01 -0.04 6237536 4084592 5038526 4542647 5963348 8231750 1660750 6521750 6671750 75 75 7500 375 7125 752000 3750000 752000 3000 4 2996 250 2 248 37500 25000 10000 12 9988 200 1 199 125000 12500 250 19 231 143 8 135 187500 75000 250 1 249 350 25 325 12500 250000 10000 12 9988 1600 2 1598 125000 20000 250 3 247 5000 30 4970 25000 300000 630 32 598 500 1 499 315000 6250 4280 5 4275 53500 1000 1 999 12500 26498 166 30789 -4457 1660750 4000 10 3990 100000 500 1 499 6250 0.0001 0.002 0.08 0.0034 0.08 0.01 0.08 0.016 0.00133 0.0019 0.02 0.0023 0.08 0.08 0.01 0.0167 0.002 0.08 0.08 0.08 0.04 0.08 78 78 115 115 444 4000 4000 265 -2612 56364 167834 -39216 2604 -92131 -5758 -5758 930 49033 32627 -902 100065 -6589 1702 2176 432 205 2274 <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 1.&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Organization</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Medifirst Solutions, Inc. ("MSI" or the "Company") was incorporated in Nevada in November 2010.&#160;&#160;The Company is in the development stage and has a diverse product line including both consumer products and digital media.&#160;&#160;The Company has a Health &amp; Wellness division with an LED Light Therapy System that it distributes.&#160;&#160;The Company plans to launch "Florida Health Community" as an on-line healthcare directory and social media site geared towards both professionals and consumers.&#160;&#160;MSI also intends to produce a tabloid size newsletter with healthcare industry related news and events.&#160;&#160;MSI holds the trademark to, and will sell on-line, the Miracle-cig<font style="display: inline; font-size: 70%; vertical-align: text-top;">TM</font>, an electronic cigarette that is tobacco free and that emits a fine water mist in place of smoke.&#160; Additionally, MSI will offer print and digital marketing and advertising services to its client base of medical professionals as well as solicit new business in other business sectors.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Basis of Presentation</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information.&#160;&#160;Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such principles and regulations of the Securities and Exchange Commission for Form 10-Q.&#160;&#160;All adjustments, consisting of normal recurring adjustments, have been made which, in the opinion of management, are necessary for a fair presentation of the results of interim periods.&#160;&#160;The results of operations for such interim periods are not necessarily indicative of the results that may be expected for a full year because of, among other things, seasonality factors in the retail business.&#160;&#160;The unaudited financial statements contained herein should be read in conjunction with the audited financial statements and notes thereto&#160;&#160;for the fiscal year ended December 31, 2012.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Revenue Recognition</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. The following policies reflect specific criteria for the various revenues streams of the Company:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenue will be recognized at the time the product is delivered or services are performed.&#160;&#160;Provision for sales returns will be estimated based on the Company's historical return experience.&#160;&#160;Revenue will be presented net of returns.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Use of Estimates</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Segment Information</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company follows Accounting Standards Codification ("ASC") 280, "Segment Reporting".&#160;&#160;The Company currently operates in a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Net Loss Per Common Share</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic net (loss) income per common share is calculated using the weighted average common shares outstanding during each reporting period.&#160;&#160;Diluted net (loss) income per common share adjusts the weighted average common shares for the potential dilution that could occur if common stock equivalents (convertible debt and preferred stock, warrants, stock options and restricted stock shares and units) were exercised or converted into common stock.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Income Taxes</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred income taxes are recognized for the tax consequences related to temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for tax purposes at each year end, based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.&#160;&#160;A valuation allowance is recognized when, based on the weight of all available evidence, it is considered more likely than not that all, or some portion, of the deferred tax assets will not be realized.&#160;&#160;Income tax expense is the sum of current income tax plus the change in deferred tax assets and liabilities.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information.&#160;&#160;A tax position that meets this more likely than not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Stock-Based Compensation</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company accounts for equity instruments issued to employees in accordance with ASC 718, Compensation - Stock Compensation.&#160;&#160;ASC 718 requires all share-based compensation payments to be recognized in the financial statements based on the fair value using an option pricing model.&#160;&#160;ASC 718 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equity instruments granted to non-employees are accounted for in accordance with ASC 505, Equity.&#160;&#160;The final measurement date for the fair value of equity instruments with performance criteria is the date that each performance commitment for such equity instrument is satisfied or there is a significant disincentive for non-performance.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Cash and Cash Equivalents</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Inventory</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inventory consists of finished goods and is stated at the lower of cost (first-in, first-out) or market value.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Equipment</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment, consisting of computer equipment, is stated at cost less accumulated depreciation.&#160;&#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, of five years.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company reviews long-lived assets, such as equipment, for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable.&#160;&#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.&#160;&#160;If the carrying amount of an asset exceeds the estimated future cash flows, an impairment loss will be recorded by the amount the carrying value exceeds the fair value of the asset.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Recent Pronouncements</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">There are no recent accounting pronouncements that apply to the Company.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 2.&#160;&#160;EQUIPMENT (NET)</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment is recorded at cost and consisted of the following at June 30, 2013 and 2012:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="font-size: 10pt; width: 80%; font-family: arial;" cellspacing="0" cellpadding="0"> <tr> <td style="padding-bottom: 2px;" valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="76%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Computer equipment</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,758</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,758</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="76%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(444</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(230</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td style="padding-bottom: 4px;" valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,314</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,528</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Depreciation for the three months ended June 30, 2013 and 2012 was $115 and $78, respectively.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 3.&#160;&#160;LOANS PAYABLE - STOCKHOLDERS</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the period ended June 30, 2013 a stockholder of the Company advanced the Company $9,757 to pay for certain expenses.&#160;&#160;The loan has a balance of $16,312 at June 30, 2013, bears no interest and is payable on demand.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">At June 30, 2013 the Company was indebted to a stockholder in the amount of $5,000.&#160;&#160;The loan has an interest of 20%.&#160;&#160;Principal and accrued interest were due and payable on July 2, 2012.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">At June 30, 2013 the Company was indebted to a stockholder in the amount of&#160;&#160;$5,000.&#160;&#160;The loan has an interest of 10%.&#160;&#160;Principal and accrued interest were due and payable on June 2, 2013.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 4.&#160;&#160;6% CONVERTIBLE NOTES</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2011, the Company issued $800 aggregate principal amount of 6% convertible notes due in January 2012.&#160;&#160;Interest on the notes accrued at the rate of 6% per annum for the term of the notes and was payable upon maturity.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In June 2013, two of the note holders converted $70 of note principal into 700,000 shares of the Company's common stock.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">At any time on or after the maturity date, the holders of the notes, have the option of converting any of the unpaid principal and interest into the Company's common stock.&#160;&#160;The notes plus any accrued but unpaid interest are convertible at the rate of $0.0001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In May 2012, the Company issued a $25,000 6% per annum note that matured in November 2012.&#160;&#160;In December 2012 the note was amended to be a convertible note.&#160;&#160;Interest on the note accrues interest at 6% per annum and is payable when the note matures.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The holder of the $25,000 note has the option of converting it at any time with the approval of the Board of Directors.&#160;&#160;The note plus any accrued but unpaid interest are convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The holder of the note converted $1,010 of note principal into 1,010,000 shares of common stock as follows:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="width: 80%; font-family: arial; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Date of Conversion</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Principal </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amount </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Converted</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Conversion </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Rate</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="11%" colspan="3"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Shares </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Received</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 2012</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">150</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">150,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 2013</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">660</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">660,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">March&#160;&#160;2013</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">200</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">200,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 5.&#160;&#160;STOCKHOLDERS' EQUITY</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In November 2010, the Company issued 752,000 shares of common stock at par value for services provided to the Company.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In November 2010, the Company issued 81,250 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In November 2010, the Company issued 37,500 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 125,000 shares of common stock at $0.08 per share.</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font>&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 187,500 shares of common stock at $0.00133 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 12,500 shares of common stock at $0.02 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 125,000 shares of common stock at $.08 per share for services provided to the Company.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 25,000 shares of common stock at $0.01 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2010, the Company issued 315,000 shares of common stock at $0.002 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In January 2011, the Company issued 250,000 shares of common shares at $0.0034 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In January 2011, the Company issued 25,000 shares of common shares at $0.01 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In January 2011, the Company issued 12,500 shares of common shares at $0.016 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2011 the Company issued 75,000 shares of common stock at $0.0019 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2011 the Company issued 250,000 shares of common stock at $0.0014 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2011, the Company issued 3,750,000 shares of common stock to an officer of the Company for services provided to the Company at $0.002 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In April 2011, the Company issued 300,000 shares of common stock at $0.0167 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In October 2011, the Company issued 20,000 shares of common stock at $0.08 per share for services provided to the company.</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font>&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In October 2011, the Company issued 6,250 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In November 2011, the Company issued 53,500 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In November 2011, the Company issued 12,500 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2011, the Company issued 100,000 shares of common stock at $0.04 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2011, the Company issued 6,250 shares of common stock at $0.08 per share.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In December 2012, the Company issued 150,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In January 2013, the Company issued 660,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2013, the Company issued 200,000 shares of common stock at $0.001 per share as partial conversion of a note (See note 4).</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In June 2013, the Company issued 700,000 shares of common stock at $0.0001 per share as partial conversion of a note (See note 4).</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 6.&#160;&#160;INCOME TAXES</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes.&#160;&#160;The sources and tax effects of the differences are as follows:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="width: 80%; font-family: arial; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="88%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font> <div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Income tax provision at the federal&#160;<font style="display: inline; font-family: times new roman; font-size: 10pt;">statutory rate</font></font></font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="text-align: right;" valign="bottom" width="9%"> <div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;39</font></div> </td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div> </td> </tr> <tr bgcolor="white"> <td style="text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;" valign="bottom" width="88%"> <div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Effect of operating losses</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"> <div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(39</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)%</font></div> </td> </tr> <tr bgcolor="#cceeff"> <td style="padding-bottom: 4px;" valign="bottom" width="88%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 4px double;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;0</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of June 30, 2013, the Company has a net operating loss carryforward of approximately $250,000.&#160;&#160;This loss will be available to offset future taxable income.&#160;&#160;If not used, this carryforward will begin to expire in 2030. The deferred tax asset relating to the operating loss carryforward has been fully reserved at June 30, 2013.&#160;&#160;The principal difference between the operating loss for income tax purposes and reporting purposes results from the issuance of common shares for services.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 7.&#160;&#160;BASIS OF REPORTING</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company's financial statements are presented on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company has experienced a loss from operations during its development stage as a result of its investment necessary to achieve its operating plan, which is long-range in nature.&#160;&#160;For the period from inception to June 30, 2013, the Company incurred a net loss of approximately $265,000.&#160;&#160;In addition, the Company has no significant assets or revenue generating operations.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company currently does not have sufficient cash to sustain itself for the next 12 months, and will require additional funding in order to execute its plan of operations and to continue as a going concern.&#160;&#160;To meet its cash needs, management expects to raise capital through a private placement offering.&#160;&#160;In the event that this funding does not materialize, certain stockholders have agreed, orally, to loan, on a non-interest bearing demand basis, sufficient funds to maintain the Company's operations for the next 12 months.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Organization</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Medifirst Solutions, Inc. ("MSI" or the "Company") was incorporated in Nevada in November 2010.&#160;&#160;The Company is in the development stage and has a diverse product line including both consumer products and digital media.&#160;&#160;The Company has a Health &amp; Wellness division with an LED Light Therapy System that it distributes.&#160;&#160;The Company plans to launch "Florida Health Community" as an on-line healthcare directory and social media site geared towards both professionals and consumers.&#160;&#160;MSI also intends to produce a tabloid size newsletter with healthcare industry related news and events.&#160;&#160;MSI holds the trademark to, and will sell on-line, the Miracle-cig<font style="display: inline; font-size: 70%; vertical-align: text-top;">TM</font>, an electronic cigarette that is tobacco free and that emits a fine water mist in place of smoke.&#160; Additionally, MSI will offer print and digital marketing and advertising services to its client base of medical professionals as well as solicit new business in other business sectors.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Revenue Recognition</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In general, the Company records revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. The following policies reflect specific criteria for the various revenues streams of the Company:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Revenue will be recognized at the time the product is delivered or services are performed.&#160;&#160;Provision for sales returns will be estimated based on the Company's historical return experience.&#160;&#160;Revenue will be presented net of returns.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Use of Estimates</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Segment Information</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company follows Accounting Standards Codification ("ASC") 280, "Segment Reporting".&#160;&#160;The Company currently operates in a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</font></div> <div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Net Loss Per Common Share</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Basic net (loss) income per common share is calculated using the weighted average common shares outstanding during each reporting period.&#160;&#160;Diluted net (loss) income per common share adjusts the weighted average common shares for the potential dilution that could occur if common stock equivalents (convertible debt and preferred stock, warrants, stock options and restricted stock shares and units) were exercised or converted into common stock.</font></div> <div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Income Taxes</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Deferred income taxes are recognized for the tax consequences related to temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for tax purposes at each year end, based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income.&#160;&#160;A valuation allowance is recognized when, based on the weight of all available evidence, it is considered more likely than not that all, or some portion, of the deferred tax assets will not be realized.&#160;&#160;Income tax expense is the sum of current income tax plus the change in deferred tax assets and liabilities.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information.&#160;&#160;A tax position that meets this more likely than not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Stock-Based Compensation</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company accounts for equity instruments issued to employees in accordance with ASC 718, Compensation - Stock Compensation.&#160;&#160;ASC 718 requires all share-based compensation payments to be recognized in the financial statements based on the fair value using an option pricing model.&#160;&#160;ASC 718 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from initial estimates.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equity instruments granted to non-employees are accounted for in accordance with ASC 505, Equity.&#160;&#160;The final measurement date for the fair value of equity instruments with performance criteria is the date that each performance commitment for such equity instrument is satisfied or there is a significant disincentive for non-performance.</font></div> <div style="text-indent: 0pt; display: block;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Cash and Cash Equivalents</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Recent Pronouncements</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">There are no recent accounting pronouncements that apply to the Company.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Equipment</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment, consisting of computer equipment, is stated at cost less accumulated depreciation.&#160;&#160;Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, of five years.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The Company reviews long-lived assets, such as equipment, for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable.&#160;&#160;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset.&#160;&#160;If the carrying amount of an asset exceeds the estimated future cash flows, an impairment loss will be recorded by the amount the carrying value exceeds the fair value of the asset.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table align="left" style="font-size: 10pt; width: 80%; font-family: arial;" cellspacing="0" cellpadding="0"> <tr> <td style="padding-bottom: 2px;" valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2013</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2012</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="76%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Computer equipment</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,758</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,758</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="76%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Less: accumulated depreciation</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(444</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(230</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></td> </tr> <tr bgcolor="white"> <td valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td style="padding-bottom: 4px;" valign="bottom" width="76%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,314</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,528</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table align="left" style="font-size: 10pt; width: 80%; font-family: arial;" cellspacing="0" cellpadding="0"> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="88%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font> <div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Income tax provision at the federal&#160;<font style="display: inline; font-family: times new roman; font-size: 10pt;">statutory rate</font></font></font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="text-align: right;" valign="bottom" width="9%"> <div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;39</font></div> </td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div> </td> </tr> <tr bgcolor="white"> <td style="text-align: left; padding-bottom: 2px; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;" valign="bottom" width="88%"> <div style="text-align: left; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Effect of operating losses</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"> <div style="text-align: right; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(39</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)%</font></div> </td> </tr> <tr bgcolor="#cceeff"> <td style="padding-bottom: 4px;" valign="bottom" width="88%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 4px double;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;0</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">%</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> Five years 5758 5758 5758 5758 230 444 7627 -902 26312 0.06 0.06 0.06 0.06 0.20 0.10 0.0001 0.001 0.001 0.001 0.001 0.001 0.001 1010000 150000 660000 200000 700000 0.0999 0.39 -0.39 0.00 250000 25650 24720 <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Basis of Presentation</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information.&#160;&#160;Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such principles and regulations of the Securities and Exchange Commission for Form 10-Q.&#160;&#160;All adjustments, consisting of normal recurring adjustments, have been made which, in the opinion of management, are necessary for a fair presentation of the results of interim periods.&#160;&#160;The results of operations for such interim periods are not necessarily indicative of the results that may be expected for a full year because of, among other things, seasonality factors in the retail business.&#160;&#160;The unaudited financial statements contained herein should be read in conjunction with the audited financial statements and notes thereto&#160;&#160;for the fiscal year ended December 31, 2012.</font></div> 1 892 1475 5900 150 15 135 660 66 594 150000 660000 0.001 0.001 9175 800 25000 January 2012. November 2012. 81250 250000 81250 125000 187500 12500 12500 25000 315000 37500 250000 25000 12500 75000 250000 3750000 300000 20000 6250 53500 12500 100000 6250 150000 660000 200000 700000 0.08 0.08 0.00133 0.02 0.08 0.01 0.002 0.08 0.0034 0.01 0.016 0.0019 0.0014 0.002 0.0167 0.08 0.08 0.08 0.08 0.04 0.08 0.001 0.001 0.001 0.0001 6500 8 6492 850 25 825 48171 641 51987 -4457 6415500 6415500 48171 641 51987 -4457 447 4347 4347 9757 <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div align="center"> <table style="width: 80%; font-family: arial; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Date of Conversion</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Principal </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amount </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Converted</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Conversion </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Rate</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="11%" colspan="3"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Shares </font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Received</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">December 2012</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">150</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">150,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 2013</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">660</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">660,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">March&#160;&#160;2013</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">200</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.001</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">200,000</font></td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> 1010 150 660 200 70 200000 200 20 180 0.001 The notes plus any accrued but unpaid interest are convertible at the rate of $0.0001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013. The note plus any accrued but unpaid interest are convertible at the rate of $0.001 per share at the time of conversion up to a maximum of 9.99% of the then issued and outstanding common stock, or 814,943 shares at June 30, 2013. 4000 70 70 70 700000 0.001 <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; text-decoration: underline;">Inventory</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Inventory consists of finished goods and is stated at the lower of cost (first-in, first-out) or market value.</font></div> 814943 Begin to expire in 2030. 25000 -930 24720 <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Note 8. SUBSEQUENT EVENTS</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In July 2013, two notes were partially converted into 750,000 shares of the Company's common stock at the conversion rate of $0.001 per share.</font></div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In August 2013, one note was partially converted into 300,000 shares of the Company's common stock at the conversion rate of $0.001 per share.</font></div> 750000 300000 2 1 EX-101.SCH 6 medf-20130630.xsd 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Statement of Stockholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 007 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significat Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Equipment (Net) link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Loan Payable - Stockholder link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - 6% Convertible Notes link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Basis of Reporting link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Summary of Significat Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Equipment (Net) (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - 6% Convertible Notes (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Summary of Significat Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Equipment (Net) (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Equipment (Net) (Details Textual) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Loan Payable - Stockholder (Details) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - 6% Convertible Notes (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - 6% Convertible Notes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Basis of Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 medf-20130630_cal.xml EX-101.DEF 8 medf-20130630_def.xml